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Abstract 
Monoclonal antibodies (mAbs) to proprotein convertase subtilisin/kexin type 9 (PCSK-9) can further 
lower LDL-C by >60% in statin-treated patients.  Preliminary data suggest they may reduce 
cardiovascular (CVD) events.  Ongoing PCSK-9 mAb cardiovascular outcomes trials could provide the 
opportunity to determine whether a “legacy effect” similar to that observed for statins will occur over 
the post-trial observation period.  We hypothesize these trials could demonstrate that (1) very 
aggressive LDL-C lowering with PCSK-9 mAbs added to background statin therapy will induce extensive 
atherosclerosis stabilization and regression in the large majority of treated patients, and (2) continued 
maintenance therapy with high intensity statin therapy (with or without ezetimibe) should then inhibit 
new plaque formation, with a long-term prevention of CVD events.  The necessity of expensive lifetime 
treatment with PCSK-9 inhibitors could then be avoided in all but a small subset of patients who could 
benefit from longer treatment.   
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Statins  reduce the risk of cardiovascular  events in patients with clinical atherosclerotic 
cardiovascular disease but many patients remain at increased risk of recurrent events.(1).  Monoclonal 
antibodies (mAbs) to proprotein convertase subtilisin/kexin type 9 (PCSK-9 can further lower LDL-C by 
60% or more when added to background statin therapy, and preliminary data from shorter-term follow-
up of efficacy/safety trials suggest they further reduce recurrent CVD events in high risk patients by 
about 50% over a treatment period of 11-18 months.(2, 3)  While PCSK-9 mAbs hold the promise of 
great clinical benefit for a significant number of patients, they are  very expensive  drugs (approximately 
US$14,000 per year)(4).   We propose testing a new paradigm for cardiovascular prevention that moves 
away from lifetime preventive therapy and capitalizes on a substantial impact on a legacy effect 
cardiovascular events over the long-term, thereby  minimizing the expenditures for these new drugs 
while capturing the benefit .  Extended follow-up of the large ongoing cardiovascular outcomes trials of 
PCSK-9 mAbs provide just such an opportunity. (5-8)  We hypothesize that (1) very aggressive LDL-C 
lowering with PCSK-9 mAbs added to background statin therapy during the trials will promote 
atherosclerosis stabilization and lesion regression in treated patients, and (2) continued maintenance 
therapy with high intensity statin therapy (with or without ezetimibe) should inhibit new plaque 
formation, with long-term prevention of CVD events.  Therefore, it may be possible for shorter-term 
PCSK-9 inhibitor therapy could be sufficient for the large majority of patients, and the necessity of 
lifetime treatment with PCSK-9 inhibitors avoided in all but a small subset of patients.   
 
Legacy effects  
Meta-analysis of post-trial follow-up of the statin trials found long-term reductions in the 
relative risk of recurrent CVD events after discontinuation of statin therapy, with a magnitude of relative 
risk reduction similar to that observed in the active treatment period of the trial in primary and 
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secondary prevention trials.(9, 10)    This may suggest persistent benefit from statin-induced plaque 
stabilization and reduction in plaque volume through regression, a phenomenon observed in the 
coronary intravascular ultrasound trials.  This concept raises the possibility that more marked LDL-C 
reductions with PCSK-9 mAbs may have an even greater impact on plaque burden and disease 
stabilization and hence exhibit an even more profound “legacy effect”.   In support of this hypothesis, 
meta-analyses have found that statin therapy reduces fibrous plaque volume and improves vascular 
remodeling by virtual histology ultrasound, with plaque regression occurring after an average 19 months 
of treatment.(11, 12)   Meta-analysis of high intensity statin coronary intravascular ultrasound trials has 
found that the lower the achieved LDL-C levels, the greater the magnitude of plaque regression down to 
an LDL-C level of 15 mg/dl (Figure 1). (13) Optical coherence tomography reveals more stable plaque 
features in patients with very low on-treatment LDL-C levels.(14)  Other These vascular changes are 
consistent with the greater reduction in CVD events observed when progressively lower levels of LDL-C 
levels to <50 mg/dl were achieved in statin CVD outcomes trials of 2-6 years duration.(15)  
 
PCSK-9 mAbs  
Notably, when added to maximal statin or other lipid-lowering therapy in high risk patients, 
PCSK-9 mAbs lower LDL-C an additional 60-65% and result in achieved average LDL-C levels of 35-50 
mg/dl.(2, 3, 16)  Over 40% of patients on high intensity statins achieved persistent reductions in LDL-C 
<25 mg/dl with the addition of a PCSK-9 mAb.(16)  
In preliminary analyses of Phase 3 efficacy/safety trials of the PCSK-9 mAbs, alirocumab and 
evolocumab, these remarkable reductions in LDL-C appear to have resulted in CVD event reductions of 
approximately 50% over a period of 11-18 months.(2, 3)  Both drugs reduced LDL-C by an additional 60% 
when added to background therapy.  An early separation of the event curves was observed in both 
studies.  A meta-analysis of events reported in 24 phase 2 and 3 efficacy/safety trials of evolocumab and 
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alirocumab (n=10,159) found a preliminary suggestion that PCSK-9 mAbs may also reduce cardiovascular 
and total mortality.(17)  
The further reduction in CVD events when PCSK-9 mAbs are added to statin therapy is at least 
the magnitude expected from the degree of LDL-C lowering when compared to the statin trials.  The 
Cholesterol Treatment Trialists’ meta-analysis of statin trials found that each 39 mg/dl (1 mmol/L) 
reduction in LDL-C was associated with a 21% reduction in major cardiovascular events.(18)  The average 
70 mg/dl reduction in LDL-C reduced cardiovascular events by 50% in the PCSK-9 trials.  Thus, it appears 
the cardiovascular risk reduction from PCSK-9 inhibitors is at least as much as expected from a similar 
magnitude of LDL-C reduction from statins (eg, a 38% relative risk reduction in cardiovascular events 
expected for a 70 mg/dl reduction in LDL-C).  Ezetimibe is another LDL-C lowering drug shown to 
modestly reduce cardiovascular events in relationship to the modest magnitude of LDL-C lowering.(19)   
Along with data from a trial of  intestinal bypass surgery and diet,  this suggests statin’s pleiotropic 
effects are unlikely to be contributing additional risk reduction  benefit(20), and that LDL-C lowering 
with PCSK-9 mAbs is likely to have analogous effects on plaque stabilization and regression as a function 
of the magnitude of LDL-C lowering.  On the other hand, whether the anti-inflammatory effects of 
statins are mediated by LDL-C lowering, and if these same anti-inflammatory effects occur with PCSK-9 
mAbs remains to be determined. (21)  No cardiovascular imaging trials have yet been completed with 
PCSK-9 mAbs, although  a coronary intravascular ultrasound trial is underway with evolocumab.(22)  
However, based on the reduction in cardiovascular outcomes observed to date, it appears that PCSK-9 
mAbs are likely to result in further plaque regression and stabilization in statin-treated patients.   
Further plaque stabilization and regression with the addition of a PCSK-9 inhibitor to statin 
therapy is supported by animal data that have found more plaque regression, along with a greater 
proportion of stable plaque, occurs from the addition reduction in LDL-C.(23)  The PCSK-9 inhibitor 
alirocumab has been shown to reduce apolipoprotein B-containing lipoproteins, atherosclerotic lesion 
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size and severity, and to increase lesion stability in APOE*3Leiden.CETP mice fed a Western diet. (24)  
The distribution of plaque was reversed in alirocumab+atorvastatin treated animals, with about 75% of 
lesions in the undiseased state compared to about 75% in the severe state  in untreated animals.  
Alirocumab improved plaque morphology by reducing monocyte recruitment and content of 
macrophages and necrotic core, and increasing smooth muscle and collagen content.  These effects 
occurred after 18 weeks of alirocumab treatment and were enhanced when added to atorvastatin 
therapy, with an 89% reduction in lesion size in that group.  Lesion area correlated well with cholesterol-
lowering.  These findings are consistent with animal models where atherosclerotic changes resulting 
from a high cholesterol diet regress when animals are returned to a standard diet.(23) 
 
Proving the hypothesis 
 Continued follow-up of study participants once the ongoing PCSK-9 mAb cardiovascular 
outcomes trials end will provide a critical opportunity to test a new paradigm for cholesterol treatment: 
Is there a legacy effect after a period of profound LDL-C lowering?  Planned post-trial follow-up can 
document whether shorter term therapy (2-4 years) with PCSK-9 mAbs will result in a long term 
reduction in cardiovascular events once treatment is stopped and patients are maintained long-term on 
maximal statin therapy.  It is unlikely there will be large-scale cross-over to PCSK-9 mAbs after the end of 
the trial given the likelihood of high cost and restrictive access, at least over the nearer term, providing 
the opportunity for a natural experiment if post-trial follow-up is through a planned long-term 
observational program.  Such follow-up would also provide the opportunity to collect biomarkers or 
perform imaging that could be used to identify patients at high risk of another cardiovascular event who 
could benefit from continued PCSK-9 treatment.  In several countries, record linkage provides a cost-
effective method of obtaining robust mortality data over the very long-term.(25)  Other methods of 
regular follow-up have been successful for large epidemiologic studies and registries (26, 27).  Planned 
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post-trial follow-up would also facilitate a randomized trial of biomarker or imaging-guided treatment to 
evaluate whether continued PCSK-9 mAb treatment will further reduce cardiovascular risk in study 
participants who are identified as being at persistently high risk of recurrent events at the end of the 
trial through clinical characteristics, biomarkers, or imaging evidence of unstable plaque.  18F-NaF PET-CT 
has recently been identified as a particularly promising noninvasive measure of unstable plaque.(28)   
After the end of the PCSK-9 outcomes trial treatment period, participants are very likely to 
continue maximal statin or statin/ezetimibe therapy as the standard of care therapy.  Prevention of new 
plaque formation is the second important component of the new treatment paradigm.  Epidemiologic 
evidence suggests atherosclerotic lesions are unlikely to form when non-HDL-C levels are <125 mg/dl 
(corresponding to LDL-C <95 mg/dl) through middle-adulthood.(29) Whether this same phenomenon 
occurs in those with an  extensive burden of atherosclerosis such as those  enrolled in the PCSK-9 mAb 
trials remains to be determined.    In addition, longer-term follow-up will reveal whether there is an LDL-
C level that results in prevention of new lesion formation.   
Animal studies may be helpful in supporting the new paradigm of time-limited but very intensive 
LDL-C lowering.  Studies evaluating plaque morphology after the discontinuation of aggressive lipid-
lowering therapy while maintained on background statin therapy will be an important area for future 
investigation.(23)  To our knowledge, such trials have not been performed to date.   
 
Other drugs in development 
This strategy could be investigated for other lipid-modifying agents under development, such as 
cholesteryl ester transfer protein (CETP) inhibitors which have been shown to have similar effects to 
PCSK-9 mAbs plaque regression in animal models which re mediated by non-HDL-C lowering. (30)  In 
humans, a similar relationship with achieved non-HDL-C level and a reduction in cardiovascular events 
was observed in the statin trials.(15)   If shown to reduce cardiovascular events in ongoing trials,(31, 32) 
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and with long-term follow-up, these drugs could be used in a similar fashion as proposed for PCSK-9 
mAbs. 
 
Clinical implications 
 We have proposed a new paradigm for cardiovascular prevention that could be supported by 
data from ongoing cardiovascular outcomes trials of PCSK-9 mAbs.  After an initial period of 
atherosclerosis stabilization through shorter-term, very aggressive LDL reduction during the trial, long-
term post-trial follow-up may document persistent risk reductions after the PCSK-9 mAb therapy has 
been discontinued(a “legacy effect”), while  the patient remains maintenance statin therapy.  These 
data may provide a potent, more cost-effective  strategy for long-term cardiovascular risk reduction 
since the cost of 2-4 years of PCSK-9 inhibitor therapy (depending on the length of the randomized, 
controlled trial treatment period) could  then amortized over periods of time as long as 10 years off the 
PCSK-9 mAb.  For example, if the preliminary results of the PCSK-9 efficacy/safety trials are 
substantiated, and a 50% relative risk reduction during the trial is sustained off the PCSK-9 mAb  over a 
period of up to 10 years, this could result in marked reductions in risk for patients across the spectrum 
of cardiovascular risk.  As shown in Table 1, a consistent 50% reduction in the relative risk of a 
cardiovascular event would result in a number-needed-to-treat of 10 or less to prevent one event after 
10 years for patients with 20% 10-year cardiovascular risk, such as those with clinical ASCVD on a 
statin.(33)  This approach could also be evaluated in younger patients with heterozygous familial 
hypercholesterolemia, where a period of intensive plaque regression and stabilization might be followed 
by less intensive therapy to maintain LDL-C levels of approximately 100 mg/dl.   Therefore, it is possible 
that the cost of expensive drugs used for a limited period (2-3 years) could be averaged over a longer 
period, and prove cost-effective.   
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Figure 1.  Change in percent (PAV) and total atheroma volume (TAV) by coronary intravascular 
ultrasound by achieved mean LDL-C level on treatment with 18-24 months of rosuvastatin 40 mg or 
atorvastatin 80 mg (n=1881).  Adapted from Puri R, Nissen SE, et al.  Am J Cardiol 2014; 114: 1465-
1472.(13) 
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Table 1.  Number-needed to treat to prevent 1 CVD event.  As an example, patients with 20% 10-year 
hard cardiovascular risk would include those in the Treating-to-New-Targets trial, where the 5-year risk 
of patients with coronary heart disease were treated with atorvastatin 10 or 80 mg was 9-11%.(33)   
Adapted from Robinson J, Stone N. The 2013 ACC/AHA guideline on the treatment of blood cholesterol 
to reduce atherosclerotic cardivoascular disease risk: A new paradigm supported by more evidence. 
From Robinson JG, Stone NJ. Eur Heart J 2015 Online ahead of print May 20, 2015:doi: 
10.1093/eurheartj/ehv182.(34) 
5-
year 
CVD 
rate 
5-year NNT  
10-
year 
CVD 
rate 
10-year NNT  
LDL-C reduction (mg/dl) 
LDL-C reduction (mg/dl) 
18 26 35 44 61 
 18 26 35 44 61 
 
Relative risk reduction Relative risk reduction 
10% 15% 20% 25% 35% 50% 10% 15% 20% 25% 35% 50% 
25% 40 27 20 16 11 8 50% 20 13 10 8 6 4 
20% 50 33 25 20 14 10 40% 25 17 13 10 7 5 
15% 67 44 33 27 19 13 30% 33 22 17 13 10 7 
10% 100 67 50 40 29 20 20% 50 33 25 20 14 10 
5% 200 133 100 80 57 40 10% 100 67 50 40 29 20 
 
